Akari Therapeutics, Plc Operating Cash Flow
Akari Therapeutics, Plc (AKTX) reported Operating Cash Flow of -$5.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Akari Therapeutics, Plc net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.11M.
- Akari Therapeutics, Plc net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.49M.
- Akari Therapeutics, Plc net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.04M.
- Akari Therapeutics, Plc net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.12M.
- Akari Therapeutics, Plc net cash provided by (used in) operating activities for fiscal 2025 was -$10.57M.
- Akari Therapeutics, Plc net cash provided by (used in) operating activities for fiscal 2024 was -$12.55M.
- Akari Therapeutics, Plc net cash provided by (used in) operating activities for fiscal 2023 was -$16.43M.
- Akari Therapeutics, Plc net cash provided by (used in) operating activities for fiscal 2014 was -$1.48M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed | Net Cash Provided by (Used in) Operating Activities 99 month | Net Cash Provided by (Used in) Operating Activities 111 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$5.60M 10-Q · filed 2026-08-13 | -$8.64M derived: sum of 3 quarters · filed 2026-08-13 | -$10.76M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2026-03-31 | -$2.49M 10-Q · filed 2026-05-19 | -$5.53M derived: sum of 2 quarters · filed 2026-05-19 | -$7.65M derived: sum of 3 quarters · filed 2026-05-19 | -$10.91M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-12-31 | -$3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$5.16M derived: sum of 2 quarters · filed 2026-03-30 | -$8.42M derived: sum of 3 quarters · filed 2026-08-13 | -$10.57M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | -$2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$5.38M derived: sum of 2 quarters · filed 2026-08-13 | -$7.53M 10-Q · filed 2025-11-13 | -$9.65M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-06-30 | -$3.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$5.41M 10-Q · filed 2026-08-13 | -$7.53M derived: sum of 3 quarters · filed 2026-08-13 | -$9.02M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-03-31 | -$2.15M 10-Q · filed 2026-05-19 | -$4.27M derived: sum of 2 quarters · filed 2026-05-19 | -$5.76M derived: sum of 3 quarters · filed 2026-05-19 | -$10.66M derived: sum of 4 quarters · filed 2026-05-19 | |||||
| 2024-12-31 | -$2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$3.61M derived: sum of 2 quarters · filed 2026-03-30 | -$8.51M derived: sum of 3 quarters · filed 2026-03-30 | -$12.55M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | -$1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$6.38M derived: sum of 2 quarters · filed 2025-11-13 | -$10.43M 10-Q · filed 2025-11-13 | -$14.84M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | -$4.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$8.94M 10-Q · filed 2025-08-13 | -$13.35M derived: sum of 3 quarters · filed 2025-08-13 | -$22.70M derived: sum of 4 quarters · filed 2025-08-13 | |||||
| 2024-03-31 | -$4.04M 10-Q · filed 2025-05-14 | -$8.45M derived: sum of 2 quarters · filed 2025-05-14 | -$17.80M derived: sum of 3 quarters · filed 2025-05-14 | -$15.60M derived: sum of 4 quarters · filed 2025-05-14 | |||||
| 2023-12-31 | -$4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$13.76M derived: sum of 2 quarters · filed 2025-04-15 | -$11.55M derived: sum of 3 quarters · filed 2025-04-15 | -$16.43M 10-K · filed 2025-04-15 | |||||
| 2023-09-30 | -$9.35M derived: 10-Q 9 month − 8-K 6 month · filed 2024-11-19 | -$7.14M derived: sum of 2 quarters · filed 2024-11-19 | -$12.02M 10-Q · filed 2024-11-19 | ||||||
| 2023-06-30 | $2.21M derived: 8-K 6 month − 10-Q 3 month · filed 2024-09-06 | -$2.67M 8-K · filed 2024-09-06 | -$9.57M 6-K · filed 2023-09-29 | ||||||
| 2023-03-31 | -$4.88M 10-Q · filed 2024-05-15 | ||||||||
| 2022-12-31 | -$7.49M 8-K · filed 2024-09-06 | -$21.50M 20-F · filed 2023-05-01 | |||||||
| 2022-06-30 | -$13.62M 6-K · filed 2023-09-29 | ||||||||
| 2021-12-31 | -$18.85M 20-F · filed 2023-05-01 | ||||||||
| 2021-06-30 | -$12.28M 6-K · filed 2022-09-27 | ||||||||
| 2020-12-31 | -$4.23M derived: 20-F 12 month − 20-F 9 month · filed 2023-05-01 | -$4.94M derived: sum of 2 quarters · filed 2023-05-01 | -$9.21M derived: sum of 3 quarters · filed 2023-05-01 | -$16.95M 20-F · filed 2023-05-01 | |||||
| 2020-09-30 | -$704.17K derived: 20-F 9 month − 6-K 6 month · filed 2021-04-21 | -$4.98M derived: sum of 2 quarters · filed 2021-09-22 | -$12.72M 20-F · filed 2021-04-21 | -$16.18M derived: sum of 4 quarters · filed 2022-05-16 | |||||
| 2020-06-30 | -$4.27M derived: 6-K 6 month − 20-F 3 month · filed 2021-09-22 | -$12.01M 6-K · filed 2021-09-22 | -$15.48M derived: sum of 3 quarters · filed 2022-05-16 | -$20.39M derived: sum of 4 quarters · filed 2022-05-16 | |||||
| 2020-03-31 | -$7.74M 20-F · filed 2021-04-21 | -$11.20M derived: sum of 2 quarters · filed 2022-05-16 | -$16.11M derived: sum of 3 quarters · filed 2022-05-16 | -$20.89M derived: sum of 4 quarters · filed 2022-05-16 | |||||
| 2019-12-31 | -$3.46M derived: 20-F 12 month − 20-F 9 month · filed 2022-05-16 | -$8.37M derived: sum of 2 quarters · filed 2022-05-16 | -$13.15M derived: sum of 3 quarters · filed 2022-05-16 | -$12.92M 20-F · filed 2022-05-16 | |||||
| 2019-09-30 | -$4.91M derived: 20-F 9 month − 20-F 6 month · filed 2021-04-21 | -$9.68M derived: sum of 2 quarters · filed 2021-04-21 | -$9.45M 20-F · filed 2021-04-21 | ||||||
| 2019-06-30 | -$4.77M derived: 20-F 6 month − 20-F 3 month · filed 2021-04-21 | -$4.54M 20-F · filed 2021-04-21 | |||||||
| 2019-03-31 | $228.94K 20-F · filed 2021-04-21 | ||||||||
| 2018-12-31 | -$22.77M 20-F · filed 2021-04-21 | -$22.58M 20-F · filed 2019-04-23 | |||||||
| 2018-06-30 | -$12.68M 6-K · filed 2019-08-29 | ||||||||
| 2017-12-31 | -$31.60M 20-F · filed 2020-03-31 | ||||||||
| 2017-06-30 | -$13.87M 6-K · filed 2018-09-27 | ||||||||
| 2016-12-31 | -$24.62M 20-F · filed 2019-04-23 | ||||||||
| 2016-03-31 | -$7.44M 10-Q · filed 2016-05-12 | -$14.21M derived: sum of 2 quarters · filed 2018-07-18 | -$8.91M derived: sum of 3 quarters · filed 2018-07-18 | -$10.42M derived: sum of 4 quarters · filed 2018-07-18 | |||||
| 2015-12-31 | -$6.77M derived: 20-F 12 month − 10-Q 9 month · filed 2018-07-18 | -$1.47M derived: sum of 2 quarters · filed 2018-07-18 | -$2.98M derived: sum of 3 quarters · filed 2018-07-18 | -$4.97M 20-F · filed 2018-07-18 | |||||
| 2015-09-30 | $5.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-23 | $3.79M derived: sum of 2 quarters · filed 2015-11-23 | $1.80M 10-Q · filed 2015-11-23 | $1.14M derived: sum of 4 quarters · filed 2016-05-12 | |||||
| 2015-06-30 | -$1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$3.50M 10-Q · filed 2015-08-12 | -$4.17M derived: sum of 3 quarters · filed 2016-05-12 | -$598.82K derived: sum of 4 quarters · filed 2016-05-12 | |||||
| 2015-03-31 | -$1.99M 10-Q · filed 2016-05-12 | -$2.20M 10-Q · filed 2015-05-12 | -$2.66M derived: sum of 2 quarters · filed 2016-05-12 | $910.70K derived: sum of 3 quarters · filed 2016-05-12 | -$1.42M derived: sum of 4 quarters · filed 2016-05-12 | ||||
| 2014-12-31 | -$667.98K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $2.90M derived: sum of 2 quarters · filed 2016-03-23 | $571.18K derived: sum of 3 quarters · filed 2016-03-23 | -$1.48M 10-K · filed 2016-03-23 | -$9.46M 10-K · filed 2015-02-11 | ||||
| 2014-09-30 | $3.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-23 | $1.24M derived: sum of 2 quarters · filed 2015-11-23 | -$808.85K 10-Q · filed 2015-11-23 | ||||||
| 2014-06-30 | -$2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$4.38M 10-Q · filed 2015-08-12 | |||||||
| 2014-03-31 | -$2.05M 10-Q · filed 2015-05-12 | ||||||||
| 2013-12-31 | -$5.45M 10-K · filed 2015-02-11 | -$16.20M 20-F · filed 2014-03-24 | |||||||
| 2012-12-31 | -$2.13M 10-K · filed 2015-02-11 | -$10.75M 20-F/A · filed 2013-04-19 | |||||||
| 2011-12-31 | -$1.01M 20-F · filed 2014-03-24 | ||||||||
| 2010-12-31 | -$366.00K 20-F/A · filed 2013-04-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |